Healx, Ovid Therapeutics To Enter Strategic Partnership; Terms Not Disclosed
Ovid Therapeutics (NASDAQ:OVID) ("Ovid"), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered,
5 Value Stocks In The Healthcare Sector
Understanding Value Stocks
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Ovid Therapeutics Receives Notice Of Allowance For U.S. Patent Titled ‘USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS’
https://patentcenter.uspto.gov/#!/applications/17066389/ifw/docs
Ovid Therapeutics Q3 EPS $(0.17) Up From $(0.28) YoY
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share. This is a 39.29 percent increase over losses of $(0.28) per share from the same period last year.
Ovid Therapeutics Granted U.S. Patent Titled ‘Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=4216&f=G&l=50&d=PTXT&p=85&S1=20210928&OS=20210928&RS=20210928
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $4
Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target from $4.5 to $4.